Anti-CD38 (Isatuximab) Humanized Antibody

Anti-CD38 (Isatuximab) Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a human IgG1 kappa monoclonal antibody that targets CD38, a type II transmembrane glycoprotein that is expressed on lymphoid cells, myeloid cells, and non-hematopoietic cells and performs several cell signaling functions. It is overexpressed on multiple myeloma cells. The antibody binds to CD38 and induces tumor cell death via diverse mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis. Antibody-dependent cellular cytotoxicity is mediated by the binding of the Fc region of the antibody with FcR of NK cells; complement-dependent cytotoxicity is mediated by the binding of the Fc region of the antibody with C1q, followed by the initiation of the complement cascade; antibody-dependent cellular phagocytosis is mediated by binding of the Fc region of the antibody with the FcR of the macrophage. The original biosimilar was approved for the treatment of multiple myeloma in 2020.

Immunogen Sequence:Human CD38

Target Alternative Name:ADPRC1; cADPr hydrolase 1; T10; Cluster of differentiation 38; CD38 Antigen (P45)

Species Reactivities:Human

Tag Line:A tumor biomarker that is overexpressed in multiple myeloma

Formulation:PBS pH 7.5

Purification: /

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.